Do analysts rate BJDX or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend LYRA or FEED?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend ZYXI or LYRA?

Zynex currently has a consensus price target of $3.35, suggesting a potential upside of 2,580.00%. Given Zynex's stronger consensus rating and higher possible upside, research analysts plainly believe Zynex is more favorable than Lyra Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zynex 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has preferable earnings & valuation, ZYXI or LYRA?

Zynex has higher revenue and earnings than Lyra Therapeutics. Zynex is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zynex $108.20M 0.04 $2.99M -$2.43 N/A Lyra Therapeutics $600K 1.78 -$93.43M -$19.15 N/A

Is ZYXI or LYRA more profitable?

Zynex has a net margin of -68.35% compared to Lyra Therapeutics' net margin of -5,491.17%. Zynex's return on equity of -804.30% beat Lyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zynex -68.35% -804.30% -36.67% Lyra Therapeutics -5,491.17% -1,010.91% -58.92%

Do analysts rate AEMD or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aethlon Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer AEMD or LYRA?

In the previous week, Aethlon Medical had 2 more articles in the media than Lyra Therapeutics. MarketBeat recorded 3 mentions for Aethlon Medical and 1 mentions for Lyra Therapeutics. Aethlon Medical's average media sentiment score of 0.58 beat Lyra Therapeutics' score of -0.71 indicating that Aethlon Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aethlon Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts rate LYRA or BTCY?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is LYRA or BTCY more profitable?

Biotricity has a net margin of -80.42% compared to Lyra Therapeutics' net margin of -5,491.17%. Biotricity's return on equity of 0.00% beat Lyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lyra Therapeutics -5,491.17% -1,010.91% -58.92% Biotricity -80.42% N/A -188.47%

Lyra Therapeutics (LYRA) Competitors

$0.60 -0.10 (-13.67%)

As of 11:10 AM Eastern

Compare

LYRA vs. BJDX, FEED, ZYXI, AEMD, and BTCY

Should you buy Lyra Therapeutics stock or one of its competitors? MarketBeat compares Lyra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lyra Therapeutics include Bluejay Diagnostics (BJDX), Nanovibronix (FEED), Zynex (ZYXI), Aethlon Medical (AEMD), and Biotricity (BTCY). These companies are all part of the "medical equipment" industry.

How does Lyra Therapeutics compare to Bluejay Diagnostics?

Bluejay Diagnostics (NASDAQ:BJDX) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Bluejay Diagnostics has higher earnings, but lower revenue than Lyra Therapeutics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A
Lyra Therapeutics	$600K	1.78	-$93.43M	-$19.15	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Bluejay Diagnostics had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 2 mentions for Bluejay Diagnostics and 1 mentions for Lyra Therapeutics. Bluejay Diagnostics' average media sentiment score of 0.44 beat Lyra Therapeutics' score of -0.71 indicating that Bluejay Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Bluejay Diagnostics	Neutral
Lyra Therapeutics	Negative

Bluejay Diagnostics has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Bluejay Diagnostics has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Bluejay Diagnostics' return on equity of -144.27% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 6.1% of Bluejay Diagnostics shares are held by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Bluejay Diagnostics beats Lyra Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Lyra Therapeutics compare to Nanovibronix?

Lyra Therapeutics (NASDAQ:LYRA) and Nanovibronix (NASDAQ:FEED) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

In the previous week, Nanovibronix had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 2 mentions for Nanovibronix and 1 mentions for Lyra Therapeutics. Nanovibronix's average media sentiment score of 0.78 beat Lyra Therapeutics' score of -0.71 indicating that Nanovibronix is being referred to more favorably in the news media.

Company	Overall Sentiment
Lyra Therapeutics	Negative
Nanovibronix	Positive

95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Nanovibronix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nanovibronix has higher revenue and earnings than Lyra Therapeutics. Nanovibronix is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	1.78	-$93.43M	-$19.15	N/A
Nanovibronix	$2.55M	1.29	-$18.18M	-$8.82	N/A

Lyra Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nanovibronix has a net margin of -923.20% compared to Lyra Therapeutics' net margin of -5,491.17%. Nanovibronix's return on equity of -54.25% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
Nanovibronix	-923.20%	-54.25%	-43.10%

Summary

Nanovibronix beats Lyra Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Lyra Therapeutics compare to Zynex?

Zynex (NASDAQ:ZYXI) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

In the previous week, Lyra Therapeutics had 1 more articles in the media than Zynex. MarketBeat recorded 1 mentions for Lyra Therapeutics and 0 mentions for Zynex. Zynex's average media sentiment score of 0.00 beat Lyra Therapeutics' score of -0.71 indicating that Zynex is being referred to more favorably in the media.

Company	Overall Sentiment
Zynex	Neutral
Lyra Therapeutics	Negative

29.7% of Zynex shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 49.3% of Zynex shares are held by insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Zynex has higher revenue and earnings than Lyra Therapeutics. Zynex is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zynex	$108.20M	0.04	$2.99M	-$2.43	N/A
Lyra Therapeutics	$600K	1.78	-$93.43M	-$19.15	N/A

Zynex has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

Zynex currently has a consensus price target of $3.35, suggesting a potential upside of 2,580.00%. Given Zynex's stronger consensus rating and higher possible upside, research analysts plainly believe Zynex is more favorable than Lyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zynex	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Zynex has a net margin of -68.35% compared to Lyra Therapeutics' net margin of -5,491.17%. Zynex's return on equity of -804.30% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zynex	-68.35%	-804.30%	-36.67%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Summary

Zynex beats Lyra Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Lyra Therapeutics compare to Aethlon Medical?

Aethlon Medical (NASDAQ:AEMD) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Aethlon Medical has higher earnings, but lower revenue than Lyra Therapeutics. Aethlon Medical is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aethlon Medical	N/A	N/A	-$7.15M	-$14.69	N/A
Lyra Therapeutics	$600K	1.78	-$93.43M	-$19.15	N/A

Aethlon Medical has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Aethlon Medical's return on equity of -137.73% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aethlon Medical	N/A	-137.73%	-105.87%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Aethlon Medical has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

In the previous week, Aethlon Medical had 2 more articles in the media than Lyra Therapeutics. MarketBeat recorded 3 mentions for Aethlon Medical and 1 mentions for Lyra Therapeutics. Aethlon Medical's average media sentiment score of 0.58 beat Lyra Therapeutics' score of -0.71 indicating that Aethlon Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aethlon Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lyra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aethlon Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

2.0% of Aethlon Medical shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 0.7% of Aethlon Medical shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Aethlon Medical beats Lyra Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Lyra Therapeutics compare to Biotricity?

Lyra Therapeutics (NASDAQ:LYRA) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by insiders. Comparatively, 1.6% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Biotricity has higher revenue and earnings than Lyra Therapeutics. Biotricity is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	1.78	-$93.43M	-$19.15	N/A
Biotricity	$12.06M	0.28	-$14.09M	-$0.16	N/A

In the previous week, Lyra Therapeutics had 1 more articles in the media than Biotricity. MarketBeat recorded 1 mentions for Lyra Therapeutics and 0 mentions for Biotricity. Biotricity's average media sentiment score of 0.00 beat Lyra Therapeutics' score of -0.71 indicating that Biotricity is being referred to more favorably in the news media.

Company	Overall Sentiment
Lyra Therapeutics	Negative
Biotricity	Neutral

Lyra Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market.

Biotricity has a net margin of -80.42% compared to Lyra Therapeutics' net margin of -5,491.17%. Biotricity's return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
Biotricity	-80.42%	N/A	-188.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Biotricity	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Lyra Therapeutics and Biotricity tied by winning 7 of the 14 factors compared between the two stocks.

Get Lyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LYRA vs. The Competition

Export

Metric	Lyra Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.07M	$3.02B	$6.80B	$12.58B
Dividend Yield	N/A	1.86%	2.66%	6.16%
P/E Ratio	-0.03	19.69	27.48	25.45
Price / Sales	1.78	352.53	541.47	103.18
Price / Cash	N/A	57.53	48.53	58.59
Price / Book	0.07	4.30	10.97	6.65
Net Income	-$93.43M	$64.45M	$3.57B	$336.83M
7 Day Performance	2.92%	3.37%	2.80%	3.00%
1 Month Performance	-14.29%	2.40%	1.93%	0.56%
1 Year Performance	-93.26%	33.37%	36.49%	30.42%

Lyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LYRA Lyra Therapeutics	0.234 of 5 stars	$0.60 -13.7%	N/A	-92.2%	$1.07M	$600K	N/A	50	Gap Down
BJDX Bluejay Diagnostics	0.3405 of 5 stars	$3.93 +1.7%	N/A	-82.7%	$4.04M	N/A	N/A	9
FEED Nanovibronix	0.4989 of 5 stars	$0.64 -8.2%	N/A	N/A	$3.91M	$2.55M	N/A	20	Gap Down
ZYXI Zynex	N/A	$0.13 flat	$4.90 +3,820.0%	N/A	$3.80M	$108.20M	N/A	770
AEMD Aethlon Medical	1.0988 of 5 stars	$1.40 +1.1%	N/A	-93.1%	$3.31M	N/A	N/A	10	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LYRA) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lyra Therapeutics (LYRA) Competitors

LYRA vs. BJDX, FEED, ZYXI, AEMD, and BTCY

How does Lyra Therapeutics compare to Bluejay Diagnostics?

Summary

How does Lyra Therapeutics compare to Nanovibronix?

Summary

How does Lyra Therapeutics compare to Zynex?

Summary

How does Lyra Therapeutics compare to Aethlon Medical?

Summary

How does Lyra Therapeutics compare to Biotricity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA vs. The Competition

Lyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lyra Therapeutics (LYRA) Competitors

LYRA vs. BJDX, FEED, ZYXI, AEMD, and BTCY

How does Lyra Therapeutics compare to Bluejay Diagnostics?

Which has higher valuation and earnings, BJDX or LYRA?

Do analysts rate BJDX or LYRA?

Does the media prefer BJDX or LYRA?

Which has more risk and volatility, BJDX or LYRA?

Is BJDX or LYRA more profitable?

Do institutionals & insiders have more ownership in BJDX or LYRA?

Summary

How does Lyra Therapeutics compare to Nanovibronix?

Does the media favor LYRA or FEED?

Do insiders & institutionals believe in LYRA or FEED?

Which has better valuation and earnings, LYRA or FEED?

Which has more risk and volatility, LYRA or FEED?

Do analysts recommend LYRA or FEED?

Is LYRA or FEED more profitable?

Summary

How does Lyra Therapeutics compare to Zynex?

Does the media refer more to ZYXI or LYRA?

Do institutionals & insiders hold more shares of ZYXI or LYRA?

Which has preferable earnings & valuation, ZYXI or LYRA?

Which has more volatility & risk, ZYXI or LYRA?

Do analysts recommend ZYXI or LYRA?

Is ZYXI or LYRA more profitable?

Summary

How does Lyra Therapeutics compare to Aethlon Medical?

Which has better earnings & valuation, AEMD or LYRA?

Is AEMD or LYRA more profitable?

Which has more risk & volatility, AEMD or LYRA?

Does the media prefer AEMD or LYRA?

Do analysts rate AEMD or LYRA?

Do institutionals and insiders hold more shares of AEMD or LYRA?

Summary

How does Lyra Therapeutics compare to Biotricity?

Do institutionals & insiders have more ownership in LYRA or BTCY?

Which has better earnings & valuation, LYRA or BTCY?

Does the media refer more to LYRA or BTCY?

Which has more risk and volatility, LYRA or BTCY?

Is LYRA or BTCY more profitable?

Do analysts rate LYRA or BTCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA vs. The Competition

Lyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools